Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma
Brain tumors responding to immunotherapy show a distinctive molecular signature that predicts success better than common genetic markers, guiding which patients benefit most.
This Nat Cancer study profiled 181 ICB-treated GBM samples with multi-platform sequencing, establishing that mesenchymal tumor transcriptional subtype — not TMB — predicts improved ICB benefit, with high HLA class I expression and T cell infiltration as co-markers. Acquired ICB resistance involved outgrowth of non-MES subclones, charting a mechanistic resistance trajectory distinct from chemoradiation.
What the study was
- Study design
- Multi-platform translational cohort study (bulk DNA-seq, bulk RNA-seq, snRNA-seq)
- Population
- ICB-treated glioblastoma (IDH wild-type)
- Sample size
- 181
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Nat Cancer
Why it surfaced
Nat Cancer (high-impact journal). n=181 with multi-platform profiling from Dana-Farber/Broad/Weizmann. Directly challenges TMB as ICB biomarker in GBM; identifies actionable transcriptional biomarker (MES subtype) and resistance trajectory. High unmet need disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.